Document:

Exhibit 10.91a

    
      
        
          Exhibit 10.91a

             

            Certain
              confidential information contained in this document, marked by brackets
              and the word "REDACTED" ([REDACTED]),
              has
              been omitted and filed separately with the Securities and Exchange
              Commission
              pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
              Amended.

            

            

            Amendment
              No. 1 to

            Xenogen
              License Agreement For Real-Time In Vivo Imaging Technology

            

            This
              First Amendment to the Xenogen License Agreement For Real-Time In Vivo
              Imaging
              Technology, effective November 20, 2004 (the "Agreement”),
              by
              and between Xenogen
              Corporation, with offices at 860 Atlantic Avenue, Alameda, California
              94501
              (“Xenogen”) and Gene
              Logic, Inc., a corporation with a principal place of business at 610
              Professional Drive, Gaithersburg, Maryland 20879 (“GL”) is effective as of the
              19th day of November, 2005 (the "First Amendment Effective Date").

             

            W
              I T N E S S E T H:

            

            The
              Parties desire
              to
              amend the Agreement in certain respects upon the terms and conditions
              set forth
              below. In
              consideration of the foregoing premises and the mutual covenants set
              forth
              below, the Parties do hereby amend the Agreement and otherwise agree
              as
              follows:

            

            1. Effect:
              Provided that both Parties execute this First Amendment not later than
              November
              23, 2005, this First Amendment shall be effective for all purposes
              as of the
              First Amendment Effective Date, and except as otherwise expressly modified
              by
              this First Amendment, the Agreement shall remain in full force and
              effect in
              accordance with its terms. All terms and capitalized words used in
              this First
              Amendment not otherwise defined herein shall have the same meaning
              for such
              terms as set forth in the Agreement.

            

            2. Additional
              System Purchase:
              Pursuant to Sections 2.1(b) and 3.5(a) of the Agreement, GL hereby
              purchases an
              Additional System from Xenogen for a purchase price of [REDACTED] dollars
              ($[REDACTED]) plus shipping and insurance charges. Xenogen will deliver
              and
              install the Additional System prior to December 31, 2005. 

            

            3. Amendment
              to Section 3.3 - Bioware:
              Section
              3.3 of the Agreement is hereby amended by replacing subsection (c)
              as
              follows:

            

            "(c) Consideration.
              During
              the Term, Bioware cell lines and bacterial strains will be priced at
              a
              non-refundable initial fee of [REDACTED]
              dollars
              ($[REDACTED])
              per
              cell line or strain, with a non-refundable annual renewal fee of [REDACTED]
              dollars
              ($[REDACTED])
              per
              cell line or strain. Xenogen will invoice Licensee for Bioware requested
              by Licensee upon
              shipment and annually thereafter.
              After
              Licensee has made the foregoing annual payments for Bioware for [REDACTED]
              years, Licensee will have a fully paid-up, non-exclusive, non-transferable
              license to such LPTA Model line.“

             

            
              
                
                

              

              
                
                

                
                  

                

              

              
                
                

              

            

            4. Amendment
              to Section 3.4 - LPTA®
              Animal Models:
              Section
              3.4 of the Agreement is hereby amended by replacing 

            

            “During
              the Term, LPTA Models will be priced at a non-refundable fee of [REDACTED]
              dollars
              ($[REDACTED])
              per
              animal (minimum quantity of twenty animals), or, for breeding pairs,
              a
              non-refundable initial fee of [REDACTED]
              dollars
              ($[REDACTED])
              per
              line, with a non-refundable annual renewal fee of [REDACTED]
              dollars
              ($[REDACTED])
              per
              line. As long as Licensee maintains its access rights to at least one
              such line
              during the Term, then breeding pairs for subsequent lines will be priced
              at a
              non-refundable initial fee of [REDACTED]
              dollars
              ($[REDACTED])
              per
              line, with a non-refundable annual renewal fee of [REDACTED]
              dollars
              ($[REDACTED])
              per
              line”

            with

            “During
              the Term, LPTA Models will be priced at a non-refundable fee of [REDACTED]
              dollars
              ($[REDACTED])
              per
              animal (minimum quantity of twenty animals), or breeding pairs will
              be priced at
              a non-refundable initial fee of [REDACTED]
              dollars
              ($[REDACTED])
              per
              line, with a non-refundable annual renewal fee of [REDACTED]
              dollars
              ($[REDACTED])
              per
              line. After Licensee has made the foregoing annual payments for an
              LPTA Model
              line for [REDACTED] years, Licensee will have a fully paid-up, non-exclusive,
              non-transferable license to such LPTA Model line.“

            

            5. Amendment
              to Section 3.5 - Payments:
              Section
              3.5(a) of the Agreement is hereby amended by replacing “first
              Additional System ordered within the first twelve (12) months of the
              Term, the
              price shall be the lesser of $[REDACTED]
              or
              Xenogen’s then current list price”
with
              “first
              Additional System ordered within the first twelve (12) months of the
              Term, the
              price shall be the lesser of $[REDACTED]
              or
              Xenogen’s then current list price, and for the second Additional System ordered
              before the first anniversary of the First
              Amendment Effective Date,
              the
              price shall be the lesser of $[REDACTED]
              or
              Xenogen’s then current list price”. 

            

            5. Amendment
              to Section 3.5 - Payments:
              Section
              3.5 of the Agreement is hereby amended by replacing subsection (b)
              as
              follows:

            

            “(b) Technology
              License Fee.
              Beginning on the Amendment Effective Date, in addition to the purchase
              price set
              forth in Section 3.5(a), for each Imaging System purchased by Licensee
              hereunder, Licensee shall pay a non-refundable, non-creditable, annual
              technology license fee of [REDACTED]
              dollars
              ($[REDACTED])
              to
              practice the Xenogen Imaging Technology in the Field with the Imaging
              System for
              the first year of the Term and [REDACTED]
              dollars
              ($[REDACTED])
              annually to practice the Xenogen Imaging Technology in the Field with
              each
              Imaging System for each year of the Term thereafter (e.g., for the
              Imaging
              System and an Additional System, an aggregate annual fee of $[REDACTED]);
              provided however, that if the patents included in the Xenogen Imaging
              Technology
              are declared invalid or unenforceable as they relate to the Imaging
              System in a
              final judicial or administrative opinion from which no appeal can be
              taken, such
              fee shall no longer apply. Annual license fees for each Authorized
              Site shall be
              capped at [REDACTED]
              dollars
              ($[REDACTED]).”

            

            
              
                -2-

              

              
                
                

                
                  

                

              

              
                
                

              

            

            6. Amendment
              to Section 8.1 - Term:
              Section
              8.1 of the Agreement is hereby amended by replacing “will expire three (3) years
              after the System Installation Date (the “Term”)” with “will expire three (3)
              years after the Installation Date of the most recent Additional System
              (the
“Term”).”

            

            7. Governing
              Law.
              This
              First Amendment shall be governed by, interpreted and construed in
              accordance
              with the laws of the State of California, without regard to conflicts
              of law
              principles.

            

            8. Counterparts.
              This
              First Amendment may be executed in counterparts, each of which shall
              be deemed
              to be an original and together shall be deemed to be one and the same
              document.

            

            IN
              WITNESS WHEREOF, the Parties hereby execute this First
              Amendment by their respective duly authorized representatives
              as of
              the First Amendment Effective Date.

            

            
              	
                      XENOGEN
                        CORPORATION

                    	
                      GENE
                        LOGIC INC.

                    
	 	 
	 	 
	 	 
	
                      Signature

                    	
                      Signature

                    
	 	 
	 	 
	
                      Name

                    	
                      Name

                    
	 	 
	 	 
	
                      Title

                    	
                      Title

                    

            

            

            
              
                
                

              

              
                -3-Exhibit 10.92

    
      
        
          Exhibit
            10.92

            

            Gene
              Logic 2006 Performance Year Incentive Compensation Plan
              Document

            

            I.
              Purpose

            

            The
              purpose of the Plan is to provide an incentive opportunity to eligible
              employees
              of Gene Logic Inc. and its subsidiaries (collectively referred to herein
              as
“Gene Logic”) that drive performance towards the achievement of individual and
              divisional business targets in 2006. 

            

            II.
              Plan Period

            

            The
              Plan
              period is January 1 - December 31, 2006. 

            

            III.
              Eligibility

            

            All
              full-time, non-commission Gene Logic employees who commence full-time
              employment
              by 9/30/2006 are eligible. Full-time is defined as an employee who
              works 30 or
              more hours on a regularly scheduled weekly basis. Casual or temporary
              employees
              are not full-time employees.

            

            Eligibility
              equates only to the opportunity to earn an award. Refer to section
              VI for more
              detail on the determination of an individual award.

            

            IV.
              Individual Award Target 

            

            Annual
              individual incentive targets for each eligible employee are set, based
              on the
              job grade assigned to each employee, as a percentage of such employee’s weighted
              average base salary for the performance year as reflected in the chart
              below.
              The job grade assigned to an eligible employee on 12/31/2006 determines
              the
              appropriate annual target for such employee. The target is set based
              on
              achievement of 100% of the applicable performance plan goals.

            

            Refer
              to
              Section V for information regarding how these targets relate to incentive
              pool
              funding. 

            

            
              	
                      PROFESSIONAL

                    	
                      SCIENTIFIC

                    	
                      MANAGEMENT

                    	
                      NONEXEMPT

                    	
                      ANNUAL
                        TARGET

                      (Certain
                        exceptions exist)

                    
	
                      P99

                    	
                       

                    	
                      M00

                    	
                       

                    	
                      Varies

                    
	
                      P07,
                        P08

                    	
                      SC08,
                        SC09, SC10

                    	
                      M06,
                        M07, M08

                    	
                       

                    	
                      13.00%

                    
	
                      P05,
                        P06

                    	
                      SC06,
                        SC07

                    	
                      M04

                    	
                       

                    	
                      10.50%

                    
	
                      P03,
                        P04

                    	
                      SC04,
                        SC05

                    	
                      M01,
                        M03

                    	
                       

                    	
                      8.00%

                    
	
                      P01,
                        P02

                    	
                      SC02,
                        SC03

                    	
                       

                    	
                       

                    	
                      6.00%

                    
	
                       

                    	
                       

                    	
                       

                    	
                      N01
                        - N06

                    	
                      5.00%

                    

            

            

            V.
              Funding the Incentive Pools 

            

            Gene
              Logic is divided into 3 business divisions (Genomics, Labs and DRS)
              plus
              corporate Shared Services (for which the CEO acts as division manager).
              Each
              division’s incentive baseline pool (assuming “at plan” performance) will be
              funded as follows:

            

            The
              sum
              of the 12/31/06 weighted average annual base salary for each eligible
              employee
              in such division multiplied by each such employee’s 12/31/06 individual
              incentive target. 

             

             

            
              
                
                

              

              
                1

                
                  

                

              

              
                
                

              

            

            
 

            To
              determine the division’s actual incentive pool, this baseline pool will be
              modified, up or down, based on actual division performance against
              business
              objectives. These objectives consist of multiple factors weighted as
              follows:

            

            Non-Executive
              Pools will have the following performance weights:

            	-  	
                    Genomics
                      and Labs: 40% revenue, 60% operating
                      profit/loss;

                  

            	-  	
                    DRS:
                      60% research and development, 20% business development, 20%
                      operating loss
                      and revenue;

                  

            	-  	
                    Shared
                      Services: 33.3% Genomics, 33.3% Labs, 33.3%
                      DRS;

                  

            

            Executive
              (CEO & his direct reports) Pools will have the following
              performance weights:

            	-  	
                    CEO:
                      33.3% Genomics, 33.3% Labs, 33.3% DRS;

                  

            	-  	
                    Genomics,
                      Labs and DRS General Managers: 80% for the division managed
                      by such
                      General Manager, 10% for each of the other two
                      divisions;

                  

            	-  	
                    Shared
                      Services: 33.3% Genomics, 33.3% Labs, 33.3% DRS.
                      

                  

            

            The
              objectives include thresholds below which incentive pools are
              not funded. These vary by business unit. In addition, the plan rewards
              overachievement where performance for any factor exceeds the
              2006 business objective. In such cases additional funds will be added
              to the
              incentive pool. Refer to the plan Appendices for specific details regarding
              division objectives, thresholds and overachievement calculations.

            

            VI.
              Determination of Individual Awards

            

            Actual
              individual awards will generally be determined within each division’s actual
              incentive pool based on individual performance and contribution relative to
              other members of that division and also other factors. 

            

            Individual
              performance and contribution will be assessed by management primarily
              using Gene Logic’s Performance Excellence Program in which a Personal
              Performance Factor will be determined for each employee. The application
              of the
              Personal Performance Factor to an eligible employee’s incentive opportunity may
              result in an actual incentive that could be less than target, including
              zero;
              equal to target; or more than target but the sum of individual awards
              in any
              division may not exceed that divisions’ incentive pool. The chart below
              illustrates the guidelines provided to management regarding the PPFs
              but the
              final decision as to the amount of the actual incentive award for any
              employee
              is determined by the division manager, or by his or her designated
              representative as to any part of the division, subject to that division
              manager’s final approval and the approval of the CEO.

             

            

            
              
                
                

              

              
                2

                
                  

                

              

              
                
                

              

            

            

             

            

             

            Inter-division
              transfers by employees, or movement to or from the ICP and any other
              incentive
              plan (e.g. a Gene Logic commission plan) will be managed on a case
              by case
              basis.

            

            VII.
              Payout of Awards

             

            Awards
              are scheduled to be paid out in the 1st quarter of
              2007. To be eligible to receive an award, an employee must be in an
              active or
              leave status approved by Human Resources on the last working day of
              the plan
              period (12/31/2006). Employees whose employment by Gene Logic terminates,
              whether voluntarily or involuntarily, after the last working day of
              the Plan
              period and employees who are on an approved leave status after the
              last working
              day of the Plan period but in either such case before the actual payout
              of
              awards, are eligible to receive an incentive award, subject to the
              provisions in
              paragraph VI above. 

            

            Division
              incentive pools and Personal Performance Factors cannot be calculated
              until
              after the end of the Plan period. Therefore, eligible employees whose
              employment
              terminates, either voluntarily or involuntarily, prior to the end of
              the Plan
              period will not be eligible for any award under this Plan. 

            

            All
              award
              payouts will be subject to applicable withholdings.

            

            VIII.
              Amendment or Termination of the Plan

             

            Gene
              Logic reserves full power and discretion to administer, construe, and
              interpret
              the Plan and to determine all issues regarding eligibility and amount
              of
              payment. Gene Logic may amend, supplement, supersede or terminate this
              Plan at
              any time at the discretion of executive management and/or Gene Logic’s Board of
              Directors or its Compensation Committee. The Board of Directors may
              also
              determine if and how extraordinary events will be taken into account
              in
              determining whether the plan will be funded. Further, the terms and
              conditions
              of the Plan may be altered or eliminated in subsequent years. 

             

             

            
              
                
                

              

              
                3

                
                  

                

              

              
                
                

              

            

            
 

            IX.
              Relationship of Plan to Employment

            

            This
              plan
              is not intended to create a term of employment between any employee
              and Gene
              Logic or any right to continuation of employment by Gene Logic during
              the Plan
              Period. Employment of any individual at Gene Logic may be terminated
              by either
              Gene Logic or the individual, with or without cause, at any time.

            

            X.
              Country Specific Laws

            

            Where
              local law requires any modification to what is prescribed in this Plan
              in terms
              of incentive eligibility, guidelines and/or payout of awards, local
              law must be
              adhered to. However, Gene Logic reserves the right, to the extent permitted
              or
              not prohibited by such law, to determine how the plan shall be modified
              to
              comply with such law or whether to provide alternate consideration
              as determined
              by Gene Logic in lieu of the incentive award herein specified.

            

            XI.
              Approvals:

            

            Al
              Risdorfer    

            Vice
              President of Human Resources

            

            Phil
              Rohrer    

            Chief
              Financial Officer

            

            Mark
              Gessler    

            Chief
              Executive Officer

            

            

            Board
              of
              Directors of Gene Logic Inc.

            
 

            
              
                
                

              

              
                4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}]]